Analyzing Perspective Therapeutics (NYSE:CATX) and UFP Technologies (NASDAQ:UFPT)

Perspective Therapeutics (NYSE:CATX) and UFP Technologies (NASDAQ:UFPT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Valuation & Earnings

This table compares Perspective Therapeutics and UFP Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perspective Therapeutics	$1.43 million	206.55	-$46.51 million	N/A	N/A
UFP Technologies	$461.85 million	5.17	$44.92 million	$7.01	44.36

UFP Technologies has higher revenue and earnings than Perspective Therapeutics.

Insider & Institutional Ownership

54.7% of Perspective Therapeutics shares are held by institutional investors. Comparatively, 87.3% of UFP Technologies shares are held by institutional investors. 3.5% of Perspective Therapeutics shares are held by insiders. Comparatively, 6.2% of UFP Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Perspective Therapeutics and UFP Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%
UFP Technologies	11.74%	18.92%	12.33%

Risk and Volatility

Perspective Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, UFP Technologies has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Perspective Therapeutics and UFP Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perspective Therapeutics	0	1	8	0	2.89
UFP Technologies	0	1	2	0	2.67

Perspective Therapeutics presently has a consensus price target of $15.14, indicating a potential upside of 246.52%. UFP Technologies has a consensus price target of $323.50, indicating a potential upside of 4.04%. Given Perspective Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Perspective Therapeutics is more favorable than UFP Technologies.

Summary

UFP Technologies beats Perspective Therapeutics on 7 of the 12 factors compared between the two stocks.

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

About UFP Technologies

UFP Technologies, Inc. designs and manufactures solutions for medical devices, sterile packaging, and other highly engineered custom products. The company offers protective drapes for robotic surgery, single patient use surfaces, advanced wound care, infection prevention, disposables for surgical and endoscopic procedures, packaging for medical devices, orthopedic implants, biopharma drug manufacturing, and coils for catheters; and molded components for applications in acoustic insulation, interior trim, load floors, sunshades, SUV cargo cover handles, driveshaft damping, engine and manifold covers, quarter panels, and wheel liners. It also provides molded composites for commercial aviation and military gear for use in backpack components, knee and elbow pads, eyewear, and helmets; and reusable cases and custom for applications in military ballistics panels, virtual training systems, drones, communications equipment, and rugged portable computers. In addition, the company provides engineered products and components to customers in the automotive, aerospace and defense, and industrial markets for applications in military uniform and gear components, automotive interior trim, air filtration, and protective cases and inserts. It markets and sells its products through a direct sales force. The company was founded in 1963 and is headquartered in Newburyport, Massachusetts.